FinlandFinland

Vaccine deal

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the worldwide rights to develop and commercialise what will probably be first product designed to simultaneously protect against the two most common causes of acute gastro­enteritis. Financial details were not disclosed. A joint Phase I/II clinical studies is to be initiated this year in Finland. The combined vaccine, named UMN-2003, utilises norovirus GII-4 virus-like particles and a human recombinant rotavirus VP6 protein. These are produced through a baculovirus expression system.

FinlandFinland

19.09.2009

Helsinki – According to a new survey, Finnish high-tech growth companies raised almost a51m in the first half of 2009, 17% down on the first half of 2008. Second quarter funding decreased by more than 50% from the same period in...

FinlandFinland

13.07.2009

Helsinki – The Finnish government has announced plans to introduce tax incentives for companies with high research and development activities. At the end of June, a working group from the Ministry of Employment and Economy (MEE)...

FinlandFinland

05.06.2009

Espoo – Finnish pharmaceutical and dia­gnostics company OrionA/S has agreed to pay Abbott US$18m to re-acquire the rights to the intravenous formulation of its heart failure treatment levosimendan, which is marketed as...

FinlandFinland

29.04.2009

Helsinki – The Finnish Funding Agency for Technology and Innovation (Tekes), and the forest-based industry organised in the Finnish Forest Cluster have announced the five-year-research programme “Future Refinery” (FuBio), a...

FinlandFinland

21.02.2009

Helsinki – The Finnish Government has set up a new innovation policy. As its starting point, the Science and Technology Policy Council adopted the report “Review2008” in December, which outlines Finland’s new national strategy...

FinlandFinland

07.10.2008

A Helsinki – The causes of human anxiety disorders are largely unexplored, so there are currently no targeted drugs available for treatment. That’s why Finnish researchers from the Academy of Finland Research Programme on...

FinlandFinland

14.08.2008

Helsinki – A proposal for national innovation strategy has laid down new outlines for reforming Finland’s innovation policy, and has presented an action programme for their implementation. The proposal was submitted on June 12th...

FinlandFinland

20.05.2008

Helsinki – The Technology Academy Finland, an independent foundation established by Finnish industry, has announced the 4 finalists for the 2008 Millenium Technology Prize, which is awarded for technological innovation that...

FinlandFinland

19.03.2008

Helsinki – A study conducted by the research arm of the global assurance firm Allianz SE for the Lisbon Council, a Brussels-based think tank, has concluded that Finland already fulfills all of the criteria for the so-called...

FinlandFinland

19.03.2008

Helsinki – An international research team under Prof. Rasmus Nielsen from Copenhagen University has discovered that Europeans carry significantly more deleterious mutations in their genomes than Africans. The results are based on...

Displaying results 21 to 30 out of 96

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/2/article/vaccine-deal.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.15 EUR45.9%
  • STRATEC BIOMEDICAL48.50 EUR24.8%

FLOP

  • BIOFRONTERA2.52 EUR-13.1%
  • CO.DON2.51 EUR-8.7%
  • ADDEX3.07 CHF-7.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 23.11.2014

Current issue

All issues